Category: Licensing

    By Jason Derry — MacroArray Technologies, LLC has announced that it has licensed its PCADM-1 antibody test to Abbott.  The PCADM-1 protein is a prostate specific protein that can be detected in the urine.  The protein is overexpressed in malignant prostate tumors.  Under the terms of the agreement, Abbott will develop and market…

    By Christopher P. Singer Avalon Pharmaceuticals® announced in a March 7, 2007 press release a collaboration with Merck & Co., Inc. for drug discovery, development, and commercialization of inhibitors of a target that is important in cancer development.  Avalon brings its AvalonRx® screening technology platform to the collaboration and will screen a number…

    By Mark Chael Eli Lilly and Co. (NYSE: LLY) announced today that it will acquire Hypnion, Inc. of Lexington, MA., a privately held CNS drug discovery company investigating sleep and wakefulness-alertness disorders as well as circadian rhythm abnormalities.  Financial terms of the deal, which is expected to close in 2007, were not disclosed.…

    By Mark Chael GenTel BioSciences of Madison, Wisconsin recently announced that it had raised $1.5 million USD in angel financing for development and commercialization of protein chips and assays, plus $500,000 USD to be used to complete a new partnership with a large pharmaceutical company.  However, other than the fact that the deal…

    By Mark Chael 3M, headquartered in Minnesota, recently announced that it has acquired the U.K. biotechnology firm, Acolyte Biomedica Ltd.  According to the press release dated February 14, 2007, this acquisition is a natural extension of 3M’s infection prevention technologies and 3M expects to continue expanding their diagnostic testing platforms through complementary acquisitions…

    By Jason Derry Reportlinker has announced the availability of a new report that covers strategies and information relating to creating successful licensing deals in the biotechnology industry.  The report, "Biopartnering Strategies: Maximizing returns from biotechnology deal-making," covers topics such as in-licensing and out-licensing biotechnologies, as well as biopartnering trends and strategies.  In addition,…

    By Christopher P. Singer — In a February 5, 2007 press release Regeneron Pharmaceuticals, Inc. announced that it has entered into a non-exclusive license agreement with AstraZeneca involving Regeneron's VelocImmune® antibody technology.  The license includes an upfront $20 million payment to Regeneron in addition to as many as five additional annual payments of…

    By Christopher P. Singer — In two separate collaboration agreements announced on January 31, 2007, AstraZeneca has partnered with Argenta Discovery in an effort to identify and develop improved bronchodilators, and with Palatin Technologies to develop small molecule obesity drugs. Argenta's press release states that the deal includes a $21 million payment from…

        By Jason Derry — In May 2006, XOMA Ltd. and Schering-Plough Corp. agreed to a collaboration relating to discovery and development of therapeutic monoclonal antibodies.  Under the agreement, Schering-Plough selects the targets and XOMA uses its proprietary antibody technology to discover antibodies of therapeutic interest.  On Wednesday, XOMA announced that Schering-Plough exercised…

    By Jason Derry — Trellis Bioscience, Inc. has announced an agreement with PDL BioPharma, Inc. relating to discovering monoclonal antibodies that recognize a PDL antigen.  Under the agreement, Trellis will utilize its CellSpot technology to screen for hybridomas that produce antibodies of interest.  Once particular hybridomas are identified, PDL BioPharma will attempt to…